Replies to post #56638 on Biotech Values

[DewDiligence]

Re: Your MNTA post from one year ago

The acquisition possibility becomes more likely with any one or more of the below occurring by Fall 2008:

1. M-Enox approved by FDA but is 1 of 2 or 3 generics/or the application is still pending with no other generics approved.
2. M118 data comes in positive
3. Copaxone ANDA filed with FDA/EU
4. M-Enox filed with EU

Two of these four items actually happened: #1 (by default, unfortuntaely) and #3.

#2 has been delayed to some degree, and Sandoz is keeping the plan re #4 very close to the vest for competitive reasons.